Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Rotigotine may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
What Neupro is Neupro contains the active substance rotigotine. It belongs to a group of medicines called 'dopamine agonists'. Dopamine is a messenger in the brain which is important for movement. What Neupro is used for Neupro is used in adults to treat the signs and symptoms of: • Restless Legs Syndrome (RLS) – this can be associated with discomfort in your legs or arms, urges to move around, sleep disturbance and feeling tired or sleepy during the day. These symptoms are either reduced or their duration is shortened with Neupro treatment.
2.
e Neupro
Do not use Neupro if: • you are allergic to rotigotine or any of the other ingredients of this medicine (listed in section 6) • you need to have a magnetic resonance imaging (MRI) scan (diagnostic pictures of the inside of the body, created using magnetic rather than x-ray energy) • you need 'cardioversion' (specific treatment for abnormal heart beat).
You must take your Neupro patch off just before undergoing magnetic resonance imaging (MRI) or cardioversion to avoid skin burns because the patch contains aluminium. You can put a new patch on afterwards. If any of the above apply to you, do not use Neupro. If you are not sure about this, talk to your doctor or pharmacist or nurse first. Warnings and precautions Talk to your doctor or pharmacist or nurse before using Neupro. This is because: • your blood pressure needs checking regularly while using Neupro, especially at the start of the treatment. Neupro may affect your blood pressure. • your eyes need checking regularly while using Neupro. If you notice any problems with your eyesight between checks, talk to your doctor straight away. • if you have serious liver problems, your doctor may need to change the dose. If your liver problems get worse during treatment, talk to your doctor straight away. • you may get skin problems caused by the patch – see 'Skin problems caused by the patch' in section 4. • you may feel very sleepy or fall asleep suddenly – see 'Driving and using machines' in section 2. • your symptoms of Restless Legs Syndrome may start earlier than usual, be more intense and involve other limbs. If you experience such symptoms either before or after beginning treatment with Neupro, contact your doctor as your treatment may need to be adjusted. Medicines used to treat Restless Legs Syndrome should be reduced or stopped gradually. Tell your doctor if after stopping or reducing your Neupro treatment you experience symptoms such as depression, anxiety, fatigue, sweating or pain. Loss of consciousness can occur Neupro can cause loss of consciousness. This can happen especially when you start using Neupro or when your dose is increased. Tell your doctor if you lose consciousness or feel dizzy. Changes in behaviour and abnormal thinking Neupro can cause side effects that change your behaviour (how you act). You may find it helpful to tell a member of your family or carer that you are using this medicine and ask them to read this leaflet. This is so that your family or carer can tell you, or your doctor, if they are worried about any changes in your behaviour. Tell your doctor if you or your family/carer notices you are using the drug excessively or developing craving for large doses of Neupro or other medicines used to treat Restless Legs Syndrome. See 'Changes to your behaviour and abnormal thinking' in section 4 for more information. Children and adolescents Do not give this medicine to children below 18 years of age because it is not known if it is safe or effective in this age group. Other medicines and Neupro Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines obtained without a prescription and herbal medicines. Do not take the following medicines while using Neupro – because they may decrease its effect: • 'anti-psychotic' medicines – used to treat certain mental illnesses • metoclopramide – used to treat nausea (feeling sick) and vomiting.
Talk to your doctor before using Neupro if you are taking: • sedating medicines such as benzodiazepines or medicines used to treat mental illness or depression. • medicines that lower blood pressure. Neupro may decrease blood pressure when you stand up – this effect may be worsened by the medicines used to lower blood pressure. Your doctor will let you know if it is safe to keep taking these medicines while using Neupro. Neupro with food, drink and alcohol Because rotigotine enters your bloodstream through your skin, food or drink does not affect the way this medicine is absorbed by the body. You should discuss with your doctor if it is safe for you to drink alcohol while using Neupro. Pregnancy and breast-feeding Do not use Neupro if you are pregnant. This is because the effects of rotigotine on pregnancy and the unborn baby are not known. Do not breast-feed during treatment with Neupro. This is because rotigotine may pass into your breast milk and affect your baby. It is also likely to lower the amount of milk you produce. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine. Driving and using machines Neupro may make you feel very sleepy and you may fall asleep very suddenly. If this happens, do not drive. In isolated cases, people have fallen asleep while driving and this has caused accidents. Also do not use tools or machines if you feel very sleepy – or do anything else which may put others or yourself at risk of serious injury. Neupro contains sodium metabisulphite (E223) Sodium metabisulphite (E223) may rarely cause severe hypersensitivity (allergic) reactions and bronchospasm (breathing distress caused by narrowing of the airways).
3.
How to use Neupro
Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. Which strength patches to use Neupro is available in different strength patches which release the medicine over 24 hours. The strengths are 1 mg/24 h, 2 mg/24 h and 3 mg/24 h for the treatment of Restless Leg Syndrome. • • • •
Your starting dose will be one, 1 mg/24 h patch each day. From the second week, your daily dose may be increased by 1 mg each week until you get to the right maintenance dose for you. This is when you and your doctor agree that the symptoms are being controlled well enough and the side effects of the medicines are acceptable. Please follow the instructions of the prescriber carefully. The maximum dose is 3 mg per day.
If you have to stop taking this medicine, see 'If you stop using Neupro' in section 3. How to use the Neupro patches Neupro is a patch that is put on the skin. • Make sure that you take the old patch off before putting on a new one. • Stick the new patch on a different area of the skin each day. • Leave the patch on your skin for 24 hours, then take it off and put on a new one. • Change the patches at about the same time every day. • Do not cut the Neupro patches into pieces. Where to stick the patch Put the sticky side of the patch onto clean, dry, healthy skin on the following areas as shown in grey on the pictures opposite: • Shoulder or upper arm. • Belly. • Flank (your side, between the ribs and hips). • Thigh or hip.
To avoid skin irritation • Stick the patch onto a different area of skin each day. For example, put it on the right side of your body one day, then on the left side of your body the next day. Or on your upper body one day, then on your lower body the day after that. • Do not stick Neupro on the same area of skin twice within 14 days. • Do not stick the patch on broken or damaged skin – or on skin that is red or irritated. If you still get problems with your skin because of the patch, please see 'Skin problems caused by the patch' in section 4 for more information. To prevent the patch becoming loose or falling off • Do not put the patch in an area where it can be rubbed by tight clothing. • Do not use creams, oils, lotions, powders or other skin products where you will put the patch. Also do not use them on or near a patch you are already wearing. • If you need to stick the patch to a hairy area of skin, you must shave the area at least 3 days before sticking the patch there. • If the edges of the patch lift, the patch may be taped down with adhesive medical tape. If the patch falls off, put on a new patch for the rest of the day – then replace the patch at the usual time. •
Do not let the area of the patch get hot – for example too much sunlight, saunas, hot baths, heating pads or hot-water bottles. This is because the medicine may be released faster. If you think that too much heat has been applied, contact your doctor or pharmacist.
• •
Always check that the patch has not fallen off after activities such as bathing, showering or exercising. If the patch has irritated your skin, keep that area protected from direct sunlight. This is because it may change the colour of the skin.
How to use the patch • Each patch is packed in a separate sachet. • Before opening the sachet decide where you are going to stick this new patch and check you have removed any old patch. • Stick the Neupro patch onto your skin as soon as you have opened the sachet and removed the release liner. 1. To open the sachet, hold the sachet in both hands.
2. Peel apart the foil.
3. Open the sachet.
4. Take the patch out of the sachet.
5. The sticky side of the patch is covered by a transparent release liner.
6. • Bend the patch in half. This makes the S-shaped break in the liner open up.
7. • •
8. • • •
Peel off one side of the release liner. Do not touch the sticky side of the patch with your fingers.
Hold the other half of the rigid release liner. Then put the sticky half of the patch onto your skin. Press the sticky side of the patch firmly into place.
9. Fold back the other half of the patch and remove the other side of the release liner.
10. •
Press the patch down firmly with the palm of your hand. • Keep it pressed for about 30 seconds. This makes sure the patch is touching the skin and the edges stick down well. 11. Wash your hands with soap and water straight after handling the patch.
off a used patch • Slowly and carefully peel off the used patch. • Gently wash the area with warm water and mild soap. This will remove any stickiness that stays on your skin. You can also use a little baby oil to remove any stickiness that will not wash off.
•
Do not use alcohol or other dissolving liquids – such as nail polish remover. These may irritate your skin.
If you use more Neupro than you should Using higher doses of Neupro than your doctor has prescribed may cause side effects such as feeling sick (nausea) or vomiting, low blood pressure, seeing or hearing things that are not real (hallucinations), feeling confused, very sleepy, having involuntary movements and convulsions. In such cases, contact your doctor or hospital straight away. They will tell you what to do. If you forget to change the patch at your usual time • If you have forgotten to change the patch at your usual time, change it as soon as you remember. Take off the old patch and use a new one. • If you have forgotten to stick on a new patch after removing the old one, use a new patch as soon as you remember. In both cases, use a new patch at the usual time on the following day. Do not use a double dose to make up for a forgotten dose. If you stop using Neupro Do not stop using Neupro without talking to your doctor. A sudden stop could lead to a medical condition called 'neuroleptic malignant syndrome' which could be life-threatening. The signs include: loss of muscle movement (akinesia), rigid muscles, fever, unstable blood pressure, increased heart rate (tachycardia), confusion, low level of consciousness (such as a coma). If your doctor says you should stop Neupro, the daily dose should be lowered gradually: • Restless Legs Syndrome – lowered by 1 mg every other day. If you have any further questions on the use of this medicine, ask your doctor or pharmacist or nurse.
4.
Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them. Tell your doctor or pharmacist or nurse if you notice any side effects. Side effects more likely at the start of treatment You may feel sick (nausea) and vomit at the start of treatment. These effects are usually mild or moderate and only last for a short time. Talk to your doctor if they last for a long time or if you are worried about them. Skin problems caused by the patch • You may get redness and itching on the skin where the patch has been – these reactions are usually mild or moderate. • The reactions normally go away after a few hours – once you remove the patch. • Talk to your doctor if you have a skin reaction that lasts longer than a few days or is severe. Also do this if it spreads outside the area of skin that was covered by the patch. • Avoid sunlight and solarium exposure on areas of skin showing any kind of skin reaction caused by the patch. • To help avoid the skin reactions, you should put the patch on a different area of skin every day, and only use the same area again after 14 days.
Loss of consciousness can occur Neupro can cause loss of consciousness. This can happen especially when you start using Neupro or when your dose is increased. Tell your doctor if you lose consciousness or feel dizzy. Changes in behaviour and abnormal thinking Tell your doctor if you notice any changes in behaviour, thinking or both, that are listed below. They will discuss ways of managing or reducing symptoms. You may find it helpful to also tell a member of your family or carer that you are using this medicine and ask them to read this leaflet. This is so that your family or carer can tell you, or your doctor, if they are worried about any changes in your behaviour. Neupro can cause unusual urges or cravings which you cannot resist such as the impulse, drive or temptation to do things that could harm yourself or others. These may include: • strong impulse to gamble too much – even if this seriously affects you or your family • altered or increased sexual interest and behaviour which causes significant concern to you or others
when using Neupro for Restless Legs Syndrome Tell your doctor or pharmacist if you get any of the following side effects: Very common: may affect more than 1 in 10 people • headache • feeling sick (nausea) • feeling weak (fatigue) • skin irritations under the patch such as redness and itching Common: may affect up to 1 in 10 people • itching • feeling irritable
• • • • • • • •
allergic reaction increased sex drive high blood pressure vomiting, heartburn swelling of legs and feet feeling sleepy, falling asleep suddenly without warning, difficulty in sleeping, sleep problems, having unusual dreams unable to resist the impulse to perform an action that is harmful involving excessive gambling, repetitive meaningless actions, uncontrolled shopping or spending too much binge eating (eating large amount of food in a short period of time) or compulsive eating (eating more food than normal and more than needed to satisfy hunger)
Uncommon: may affect up to 1 in 100 people • feeling agitated • feeling dizzy when standing up because of a fall in blood pressure Rare: may affect up to 1 in 1,000 people • being aggressive • disorientation Not known: it is not known how often these happen • craving large doses of medicines like Neupro – more than needed for the illness. This is known as 'dopamine dysregulation syndrome' and can lead to use of too much Neupro • seeing or hearing things that are not real (hallucinations) • nightmares • paranoia • confusion • psychotic disorders • delusion • delirium • feeling dizzy • loss of consciousness, involuntary movements (dyskinesia) • involuntary muscle spasms (convulsion) • blurry vision • visual disturbances such as seeing colours or lights • vertigo (sensation of whirling motion) • feeling of heartbeat (palpitation) • abnormal heart rhythm • low blood pressure • hiccups • constipation, dry mouth • stomach discomfort and pain • diarrhoea • redness, increased sweating • generalised itching, skin irritation • generalised rash • unable to achieve or maintain an erection • weight loss, weight increase
• • • • •
increased or abnormal liver function test results increased heart rate increased levels of creatine phosphokinase (CPK) (CPK is an enzyme found mainly in skeletal muscles) falling rhabdomyolysis (a rare severe muscle disorder which causes pain, tenderness and weakness of the muscles and may lead to kidney problems)
Talk to your doctor or pharmacist if you notice any of the side effects listed above. Reporting of side effects If you get any side effects, talk to your doctor or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via: Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
5.
Neupro
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the label and carton. Do not store above 30°C. What to do with the used and unused patches • Used patches still contain the active substance 'rotigotine', which may be harmful to others. Fold the used patch with the sticky side inwards. Put the patch in the original sachet and then throw it away safely, out of the reach of children. • Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6.
What Neupro contains The active substance is rotigotine. • 1 mg/24 h: Each patch releases 1 mg of rotigotine per 24 hours. Each patch of 5 cm2 contains 2.25 mg of rotigotine. •
3 mg/24 h: Each patch releases 3 mg of rotigotine per 24 hours. Each patch of 15 cm2 contains 6.75 mg of rotigotine.
The other ingredients are: • Poly(dimethylsiloxane, trimethylsilyl silicate)-copolymerisate, povidoneK90, sodium metabisulphite (E223), ascorbyl palmitate (E304) and DL-α-tocopherol (E307). • Backing layer: Polyester film, siliconized, aluminized, colour coated with a pigment (titanium dioxide (E171), pigment yellow 13, pigment red 166, pigment yellow 12) layer and imprinted (pigment red 146, pigment yellow 180, pigment black 7). • Release liner: Transparent fluoropolymer coated polyester film. What Neupro looks like and contents of the pack Neupro is a transdermal patch. It is thin and has three layers. It is square-shaped with rounded edges. The outside is tan-coloured and is imprinted with Neupro 1 mg/24 h or 3 mg/24 h. Neupro is available in the following pack-sizes: Cartons containing 7, 14, 28, 30 or 84 (multipack containing 3 packs of 28) patches, which are individually sealed in sachets. Not all pack sizes may be marketed. Marketing Authorisation Holder UCB Pharma Limited 208 Bath Road Slough Berkshire SL1 3WE United Kingdom Manufacturer UCB Pharma S.A. Chemin du Foriest B-1420 Braine l'Alleud Belgium This leaflet was last revised in 01/2025.
Neupro 3mg/24h Transdermal patch comes as patch containing 3mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Neupro 3mg/24h Transdermal patch is rotigotine.
Medicines with the same active substance, strength and form include: Rotigotine Luye 3 mg/24 hours Transdermal patch. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Neupro 3mg/24h Transdermal patch, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Neupro is indicated for the symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome (RLS) in adults.
Posology
The dose recommendations made are in nominal dose.
A single daily dose should be initiated at 1 mg/24 h. Depending on the individual patient response, the dose may be increased in weekly increments of 1 mg/24 h to a maximum dose of 3 mg/24 h. The need for treatment continuation should be reconsidered every 6 months.
Neupro is applied once a day. The patch should be applied at approximately the same time every day. The patch remains on the skin for 24 hours and will then be replaced by a new one at a different site of application.
If the patient forgets to apply the patch at the usual time of the day or if the patch becomes detached, another patch should be applied for the remainder of the day.
Treatment discontinuation
Neupro should be discontinued gradually. The daily dose should be reduced in steps of 1 mg/24 h with a dose reduction preferably every other day, until complete withdrawal of Neupro (see section 4.4). Following this procedure, rebound (worsening of symptoms beyond initial intensity after discontinuation of treatment) has not been observed.
Special populations
Hepatic impairment
Adjustment of the dose is not necessary in patients with mild to moderate hepatic impairment. Caution is advised when treating patients with severe hepatic impairment, which may result in lower rotigotine clearance. Rotigotine has not been investigated in this patient group. A dose reduction might be needed in case of worsening of the hepatic impairment.
Renal impairment
Adjustment of the dose is not necessary in patients with mild to severe renal impairment, including those requiring dialysis. Unexpected accumulation of rotigotine levels may also occur at acute worsening of renal function (see section 5.2).
Paediatric population
The safety and efficacy of rotigotine in children and adolescents have not yet been established. Currently available data are described in section 5.2 but no recommendation on a posology can be made.
Method of administration
Neupro is for transdermal use.
The patch should be applied to clean, dry, intact healthy skin on the abdomen, thigh, hip, flank, shoulder, or upper arm. Reapplication to the same site within 14 days should be avoided. Neupro should not be placed on skin that is red, irritated or damaged (see section 4.4).
Use and handling
Each patch is packed in a sachet and should be applied directly after the sachet has been opened. One half of the release liner should be removed and the sticky side should be applied and pressed firmly to the skin. Then, the patch is fold back and the second part of the release liner is removed. The sticky side of the patch should not be touched. The patch should be pressed down firmly with the palm of the hand for about 30 seconds, so that it sticks well.
The patch should not be cut into pieces.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Magnetic resonance imaging or cardioversion (see section 4.4).
Magnetic resonance imaging and cardioversion
The backing layer of Neupro contains aluminium. To avoid skin burns, Neupro should be removed if the patient has to undergo magnetic resonance imaging (MRI) or cardioversion.
Orthostatic hypotension
Dopamine agonists are known to impair the systemic regulation of the blood pressure resulting in postural/orthostatic hypotension. These events have also been observed during treatment with rotigotine, but the incidence was similar to that observed in placebo-treated patients.
It is recommended to monitor blood pressure, especially at the beginning of treatment, due to the general risk of orthostatic hypotension associated with dopaminergic therapy.
Syncope
In clinical studies with rotigotine, syncope has been observed at a rate that was similar to that observed in patients treated with placebo. Because patients with clinically relevant cardiovascular disease were excluded in these studies, patients with severe cardiovascular disease should be asked about symptoms of syncope and pre-syncope.
Sudden onset of sleep and somnolence
Rotigotine has been associated with somnolence and episodes of sudden sleep onset. Sudden onset of sleep during daily activities, in some cases without awareness of any warning signs, has been reported. Prescribers should continually reassess patients for drowsiness or sleepiness, as patients may not acknowledge drowsiness or sleepiness until directly questioned. A reduction of dosage or termination of therapy should be carefully considered.
Impulse control and other related disorders
Patients should be regularly monitored for the development of impulse control disorders and related disorders including dopamine dysregulation syndrome. Patients and carers should be made aware that behavioural symptoms of impulse control disorders including pathologic gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists, including rotigotine. In some patients, dopamine dysregulation syndrome was observed under the treatment with rotigotine. Dose reduction/tapered discontinuation should be considered if such symptoms develop.
Neuroleptic malignant syndrome
Symptoms suggestive of neuroleptic malignant syndrome have been reported with abrupt withdrawal of dopaminergic therapy. Therefore, it is recommended to taper treatment (see section 4.2).
Dopamine agonist withdrawal syndrome
Symptoms suggestive of dopamine agonist withdrawal syndrome (for example, pain, fatigue, depression, sweating, and anxiety) have been reported with abrupt withdrawal of dopaminergic therapy, therefore, it is recommended to taper treatment (see section 4.2).
Abnormal thinking and behaviour
Abnormal thinking and behaviour have been reported and can consist of a variety of manifestations including paranoid ideation, delusions, hallucinations, confusion, psychotic-like behaviour, disorientation, aggressive behaviour, agitation, and delirium.
Fibrotic complications
Cases of retroperitoneal fibrosis, pulmonary infiltrates, pleural effusion, pleural thickening, pericarditis and cardiac valvulopathy have been reported in some patients treated with ergot-derived dopaminergic agents. While these complications may resolve when treatment is discontinued, complete resolution does not always occur.Although these adverse reactions are believed to be related to the ergoline structure of these compounds, whether other, nonergot derived dopamine agonists can cause them is unknown.
Neuroleptics
Neuroleptics given as antiemetic should not be given to patients taking dopamine agonists (see also section 4.5).
Ophthalmologic monitoring
Ophthalmologic monitoring is recommended at regular intervals or if vision abnormalities occur.
Heat application
External heat (excessive sunlight, heating pads and other sources of heat such as sauna, hot bath) should not be applied to the area of the patch.
Application site reactions
Application site skin reactions may occur and are usually mild or moderate in intensity. It is recommended that the application site should be rotated on a daily basis (e.g. from the right side to the left side and from the upper body to the lower body). The same site should not be used within 14 days. If application site reactions occur which last for more than a few days or are persistent, if there is an increase in severity, or if the skin reaction spreads outside the application site, an assessment of the risk/benefit balance for the individual patient should be conducted.
If there is a skin rash or irritation from the transdermal system, direct sunlight on the area should be avoided until the skin heals, as exposure could lead to changes in the skin color.
If a generalised skin reaction (e.g. allergic rash, including erythematous, macular, papular rash or pruritus) associated with the use of Neupro is observed, Neupro should be discontinued.
Peripheral oedema
Peripheral oedema has been observed in clinical trials conducted in patients with RLS.
Augmentation
Augmentation may occur. Augmentation refers to the earlier onset of symptoms in the evening (or even the afternoon), increase in severity of symptoms, and spread of symptoms to involve other body parts. In long-term clinical studies with rotigotine, the majority of augmentation episodes were seen in the first and second years of treatment. Doses higher than the approved dose range for RLS should be avoided as this may lead to higher rates of augmentation (see section 5.1).
Sulphite sensitivity
Neupro contains sodium metabisulphite, a sulphite that may cause allergic-type reactions including anaphylactic symptoms and life threatening or less severe asthmatic episodes in certain susceptible people.
Because rotigotine is a dopamine agonist, it is assumed that dopamine antagonists, such as neuroleptics (e.g. phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of Neupro, and co-administration should be avoided. Because of possible additive effects, caution should be advised when patients are taking sedating medicinal products or other CNS (central nervous system) depressants (e.g. benzodiazepines, antipsychotics, antidepressants) or alcohol in combination with rotigotine.
Co-administration of L-dopa and carbidopa with rotigotine had no effect on the pharmacokinetics of rotigotine, and rotigotine had no effect on the pharmacokinetics of L-dopa and carbidopa.
Co-administration of domperidone with rotigotine had no effect on the pharmacokinetics of rotigotine.
Co-administration of omeprazole (inhibitor of CYP2C19), in doses of 40 mg/day, had no effect on the pharmacokinetics and metabolism of rotigotine in healthy volunteers.
Co-administration of rotigotine (3 mg/24 h) did not affect the pharmacodynamics and pharmacokinetics of oral contraceptives (0.03 mg ethinylestradiol, 0.15 mg levonorgestrel).
Interactions with other forms of hormonal contraception have not been investigated.
Women of childbearing potential, contraception in females
Women of childbearing potential should use effective contraception to prevent pregnancy during treatment with rotigotine.
Pregnancy
There are no adequate data from the use of rotigotine in pregnant women. Animal studies do not indicate any teratogenic effects in rats and rabbits, but embryo-toxicity was observed in rats and mice at materno-toxic doses (see section 5.3). The potential risk for humans is unknown. Rotigotine should not be used during pregnancy.
Breast-feeding
Because rotigotine decreases prolactin secretion in humans, inhibition of lactation is expected. Studies in rats have shown that rotigotine and/or its metabolite(s) are excreted in breast milk. In the absence of human data, breast-feeding should be discontinued.
Fertility
For information on fertility studies, please see section 5.3.
Rotigotine may have major influence on the ability to drive and use machines.
Patients being treated with rotigotine and presenting with somnolence and/or sudden sleep episodes must be informed not to drive or engage in activities (e.g. operating machines) where impaired alertness may put themselves or others at risk of serious injury or death until such recurrent episodes and somnolence have resolved (see also sections 4.4 and 4.5).
Summary of the safety profile
Based on the analysis of pooled placebo-controlled clinical trials comprising a total of 748 Neupro- and 214 placebo-treated patients, 65.5% of the patients on Neupro and 33.2% of patients on placebo reported at least one adverse reaction.
At the beginning of therapy dopaminergic adverse reactions such as nausea and vomiting may occur. These are usually mild or moderate in intensity and transient even if treatment is continued.
Adverse drug reactions (ADRs) reported in more than 10% of patients treated with Neupro are nausea, application site reactions, asthenic conditions and headache.
In trials where the application sites were rotated as reflected in the instructions provided in the SmPC and package leaflet, 34.2% of 748 patients using Neupro, experienced application site reactions. The majority of application site reactions were mild or moderate in intensity, limited to the application areas and resulted in discontinuation of Neupro in 7.2% of subjects.
Discontinuation rate
The discontinuation rate was studied in 3 clinical trials ranging up to 3 years in duration. The percentage of subjects discontinuing was 25-38% over the first year, 10% in the second year, and 11% in the third year. Periodic assessment of efficacy should be performed, along with evaluation of safety, including augmentation.
Tabulated list of adverse reactions
The following table covers adverse drug reactions from the pooled studies mentioned above in patients with Restless Legs Syndrome and from post-marketing experience. Within the system organ classes, adverse reactions are listed under headings of frequency (number of patients expected to experience the reaction), using the following categories: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
System/organ classes acc. to MedDRA
Very common
Common
Uncommon
Rare
Not known
Immune system disorders
Hypersensitivity, which may include angioedema, tongue oedema and lip oedema
Psychiatric disorders
Sleep attacks/sudden onset of sleep, sexual desire disordersa (incl. hypersexuality, libido increased), insomnia, sleep disorder, abnormal dreams, impulse-control disordersa,d (incl. pathological gambling, stereotypy/punding, binge eating/eating disorderb, compulsive shoppingc)
Obsessive-compulsive disorder, agitationd
Aggressive behaviour/aggressionb, disorientationd
Dopamine dysregulation syndromec, perception disturbancese (incl. hallucination, hallucination visual, hallucination auditory, illusion), nightmaree, paranoiae, confusional statee, psychotic disordere, delusione, deliriume
Nervous system disorders
Headache
Somnolence
Dizzinesse, disturbances in consciousness NECe (incl. syncope, syncope vasovagal, loss of consciousness), dyskinesiae, dizziness posturale, lethargye, convulsione
Eye disorders
Vision blurrede, visual impairmente, photopsiae
Ear and labyrinth disorders
Vertigoe
Cardiac disorders
Palpitationse, atrial fibrillatione, supraventricular tachycardiae
Vascular disorders
Hypertension
Orthostatic hypotension
Hypotensione
Respiratory, thoracic and mediastinal disorders
Hiccupse
Gastrointestinal disorders
Nausea
Vomiting, dyspepsia
Constipatione, dry mouthe, abdominal paine, diarrhoeac
Skin and subcutaneous tissue disorders
Pruritus
Erythemae, hyperhidrosise, pruritus generalisede, skin irritatione, dermatitis contacte, rash generalisede
Reproductive system and breast disorder
Erectile dysfunctione
General disorders and administration site conditions
Application and instillation site reactionsa (incl. erythema, pruritus, irritation, rash, dermatitis, vesicles, pain, eczema, inflammation, swelling, discolouration, papules, exfoliation, urticaria, hypersensitivity), asthenic conditionsa (incl. fatigue, asthenia, malaise)
Irritability, oedema peripheral
Investigations
Weight decreasede, hepatic enzyme increasede (incl. AST, ALT, GGT), weight increasede, heart rate increasede, CPK increasedd,e
Injury, poisoning and procedural complications
Falle
Musculoskeletal and connective tissue disorders
Rhabdomyolysisc
a High Level Term
b Observed in open-label studies
c Observed during post-marketing
d Observed in 2011 data pool of double-blind placebo-controlled studies
e Observed in studies performed in patients with Parkinson's disease
Description of selected adverse reactions
Sudden onset of sleep and somnolence
Rotigotine has been associated with somnolence including excessive daytime somnolence and sudden sleep onset episodes. In isolated cases “sudden onset of sleep” occurred while driving and resulted in motor vehicle accidents (see also sections 4.4 and 4.7).
Impulse control disorders
Pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists, including rotigotine (see section 4.4).
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:
Yellow Card Scheme
Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store
Symptoms
The most likely adverse reactions would be those related to the pharmacodynamic profile of a dopamine agonist, including nausea, vomiting, hypotension, involuntary movements, hallucinations, confusion, convulsions and other signs of central dopaminergic stimulation.
Management
There is no known antidote for overdose of dopamine agonists. In case of suspected overdose, removal of the patch(es) should be considered because after removal of the patch(es) the active substance input is stopped and the plasma concentration of rotigotine decreases rapidly. The patient should be monitored closely, including heart rate, heart rhythm and blood pressure.
Treatment of overdose may require general supportive measures to maintain the vital signs. Dialysis would not be expected to be beneficial as rotigotine is not eliminated by dialysis.
If it is necessary to discontinue rotigotine, this should be done gradually to prevent neuroleptic malignant syndrome.
Ask anything about Neupro 3mg/24h Transdermal patch. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.